Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

iodine I 124 hJAA-F11

A radioimmunoconjugate composed of a humanized form of the mouse monoclonal antibody JAA-F11 (hJAA-F11) directed against the alpha-O-linked galactose disaccharide and tumor-associated antigen (TAA) Thomsen-Friedenreich (TF) antigen (TF-Ag) labeled with the radioisotope iodine I 124, with potential imaging activity upon positron-emission tomography (PET). Upon administration of iodine I 124 hJAA-F11, the antibody moiety specifically targets and binds to alpha-linked TF-Ag expressed on tumor cells, thereby allowing for the visualization of TF-Ag-expressing tumors upon PET. This may facilitate the assessment of the effectiveness of hJAA-F11. In tumor cells, TF-Ag appears as the disaccharide D-galactose-beta-(1-3)-N-acetyl galactosamine (Gal-beta-(1-3)-GalNAc) that is specifically alpha linked to a serine or a threonine residue on proteins. It is overexpressed on a variety of tumor cells and its expression is associated with tumor cell adhesion, tissue invasion and aggressiveness.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:124I hJAA-F11
iodine I 124-labeled hJAA-F11
iodine-124 hJAA-F11
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search